Michaud-Robert, A.-V.; Zamagni, E.; Carlier, T.; Bailly, C.; Jamet, B.; Touzeau, C.; Moreau, P.; Kraeber-Bodere, F.; Nanni, C.; Bodet-Milin, C.
Glucose Metabolism Quantified by SUVmax on Baseline FDG-PET/CT Predicts Survival in Newly Diagnosed Multiple Myeloma Patients: Combined Harmonized Analysis of Two Prospective Phase III Trials. Cancers 2020, 12, 2532.
https://doi.org/10.3390/cancers12092532
AMA Style
Michaud-Robert A-V, Zamagni E, Carlier T, Bailly C, Jamet B, Touzeau C, Moreau P, Kraeber-Bodere F, Nanni C, Bodet-Milin C.
Glucose Metabolism Quantified by SUVmax on Baseline FDG-PET/CT Predicts Survival in Newly Diagnosed Multiple Myeloma Patients: Combined Harmonized Analysis of Two Prospective Phase III Trials. Cancers. 2020; 12(9):2532.
https://doi.org/10.3390/cancers12092532
Chicago/Turabian Style
Michaud-Robert, Anne-Victoire, Elena Zamagni, Thomas Carlier, Clément Bailly, Bastien Jamet, Cyrille Touzeau, Philippe Moreau, Françoise Kraeber-Bodere, Cristina Nanni, and Caroline Bodet-Milin.
2020. "Glucose Metabolism Quantified by SUVmax on Baseline FDG-PET/CT Predicts Survival in Newly Diagnosed Multiple Myeloma Patients: Combined Harmonized Analysis of Two Prospective Phase III Trials" Cancers 12, no. 9: 2532.
https://doi.org/10.3390/cancers12092532
APA Style
Michaud-Robert, A. -V., Zamagni, E., Carlier, T., Bailly, C., Jamet, B., Touzeau, C., Moreau, P., Kraeber-Bodere, F., Nanni, C., & Bodet-Milin, C.
(2020). Glucose Metabolism Quantified by SUVmax on Baseline FDG-PET/CT Predicts Survival in Newly Diagnosed Multiple Myeloma Patients: Combined Harmonized Analysis of Two Prospective Phase III Trials. Cancers, 12(9), 2532.
https://doi.org/10.3390/cancers12092532